Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COO 
The Cooper Companies, Inc (COO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: COO (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $83
1 Year Target Price $83
| 9 | Strong Buy |
| 2 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 11.5% | Avg. Invested days 43 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.26B USD | Price to earnings Ratio 35.17 | 1Y Target Price 83 |
Price to earnings Ratio 35.17 | 1Y Target Price 83 | ||
Volume (30-day avg) 19 | Beta 1.02 | 52 Weeks Range 61.77 - 107.84 | Updated Date 10/28/2025 |
52 Weeks Range 61.77 - 107.84 | Updated Date 10/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.08% | Operating Margin (TTM) 16.57% |
Management Effectiveness
Return on Assets (TTM) 3.79% | Return on Equity (TTM) 5.01% |
Valuation
Trailing PE 35.17 | Forward PE 15.97 | Enterprise Value 16095072619 | Price to Sales(TTM) 3.53 |
Enterprise Value 16095072619 | Price to Sales(TTM) 3.53 | ||
Enterprise Value to Revenue 3.98 | Enterprise Value to EBITDA 14.75 | Shares Outstanding 198808921 | Shares Floating 197502746 |
Shares Outstanding 198808921 | Shares Floating 197502746 | ||
Percent Insiders 0.61 | Percent Institutions 103.27 |
Upturn AI SWOT
The Cooper Companies, Inc
Company Overview
History and Background
The Cooper Companies, Inc. was founded in 1958 as Martin H. Smith Co., later becoming Cooper Laboratories, Inc. It evolved through various acquisitions and divestitures, eventually focusing on vision care (CooperVision) and women's health (CooperSurgical). Significant milestones include the expansion of its contact lens business and the acquisition of key companies in the women's health sector.
Core Business Areas
- CooperSurgical: Provides medical devices, fertility solutions, and surgical instruments focused on women's health. Offers products such as diagnostic products, surgical instruments and consumables.
- CooperVision: Develops, manufactures, and markets a wide range of contact lenses, including daily disposables, monthly lenses, and specialty lenses. CooperVision has made a name for themselves with their range of product and solutions, including Clariti, MyDay and Biofinity.
Leadership and Structure
Al White is the President and CEO. The organizational structure consists of business segments (CooperVision and CooperSurgical) with functional support areas such as finance, marketing, and operations.
Top Products and Market Share
Key Offerings
- Biofinity Contact Lenses: A family of silicone hydrogel contact lenses offered as monthly lenses. Market share is estimated around 15-20% within the monthly segment. Competitors include Alcon (ALC), Johnson & Johnson (JNJ), and Bausch + Lomb (BLCO).
- Clariti Contact Lenses: A family of silicone hydrogel contact lenses offering daily disposables, monthly lenses, and toric options. Market share is estimated around 10-15% within the silicone hydrogel segment. Competitors include Alcon (ALC), Johnson & Johnson (JNJ), and Bausch + Lomb (BLCO).
- MyDay Contact Lenses: A family of silicone hydrogel contact lenses offered as daily disposables. Market share is estimated around 8-12% within the daily disposable segment. Competitors include Alcon (ALC), Johnson & Johnson (JNJ), and Bausch + Lomb (BLCO).
- Paragard IUD: A non-hormonal intrauterine device (IUD) for contraception. Holds a significant market share in the non-hormonal IUD segment. Competitors include Bayer (BAYRY) with their hormonal IUDs.
Market Dynamics
Industry Overview
The vision care industry is characterized by ongoing innovation in contact lens materials and designs. The women's health market is growing due to increased awareness and demand for advanced medical devices and fertility solutions.
Positioning
CooperCompanies holds a strong position in both vision care and women's health, with a focus on innovation and niche markets. Its competitive advantages include a diversified product portfolio and a global distribution network.
Total Addressable Market (TAM)
The TAM for vision care is estimated to be over $10 billion. The TAM for women's health is estimated to be over $6 billion. CooperCompanies is well-positioned to capture a significant portion of these markets.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong global distribution network
- Focus on innovation
- Leading market positions in niche segments
Weaknesses
- Dependence on key products
- Exposure to regulatory risks
- Competition from larger players
- Currency exchange rate fluctuations
Opportunities
- Expanding into emerging markets
- Acquiring complementary businesses
- Developing new innovative products
- Increasing adoption of specialty lenses
Threats
- Intense competition
- Technological obsolescence
- Economic downturns
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- BAYRY
- BLCO
Competitive Landscape
CooperCompanies competes with larger players in both vision care and women's health. Its advantages include a diversified product portfolio and a strong focus on innovation. Its disadvantages include its smaller size and limited financial resources compared to its larger competitors.
Major Acquisitions
Generate Life Sciences
- Year: 2021
- Acquisition Price (USD millions): 1600
- Strategic Rationale: Expanded CooperSurgical's fertility solutions business, adding cryopreservation and genetic testing services.
Growth Trajectory and Initiatives
Historical Growth: CooperCompanies has experienced moderate growth over the past years, driven by acquisitions and organic growth in its core business segments.
Future Projections: Analyst estimates suggest continued growth in revenue and earnings, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include acquisitions of companies in the women's health space and investments in R&D for new contact lens technologies.
Summary
CooperCompanies is a strong player in both the vision care and women's health markets, with a diversified product portfolio and a global distribution network. The company's focus on innovation and niche markets has allowed it to achieve leading market positions in key segments. However, CooperCompanies faces intense competition from larger players and must continue to invest in R&D to maintain its competitive edge. The balance sheet needs to be carefully monitored considering the number of acquisitions that it has made.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company reports
- Industry analysis
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About The Cooper Companies, Inc
Exchange NASDAQ | Headquaters San Ramon, CA, United States | ||
IPO Launch date 1983-12-30 | President, CEO & Non-Independent Director Mr. Albert G. White III | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 16000 | Website https://www.coopercos.com |
Full time employees 16000 | Website https://www.coopercos.com | ||
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia; and spherical lense, including lenses that correct near and farsightedness in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including paragard contraceptive intrauterine devices; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.